Interpace Biosciences Inc. (IDXG) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, IDXG scores 64 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine at 9 of 20 (ROIC 16.2%; FCF yield 23.6%); Whale 13F Flow at 11 of 20 (institutional accumulation and options positioning); Insider Conviction at 15 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 16 of 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13 of 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor, the profile is mixed. The strongest pillars are macro fit and insider conviction, while the Fundamental Cash Engine carries the lowest score relative to its weight, meaning the cash-generation case is the weakest part of the rating despite the high FCF yield figure. The FCF yield of 23.6% is an upside-driver signal on paper, but per the SEC financials, FY 2025 free cash flow was $5.5M against a $4.1M operating income line, and the figures do not establish durability. Valuation tradeoffs center on a small market capitalization ($23.2M) and an EV/EBITDA of 4.7, which can indicate a low multiple but also reflects the limited scale and thin liquidity evidenced by a trading volume of 5,107. The Forensic Balance Sheet score of 13 of 20 suggests a moderate, not distressed, financial posture, though cash of $2.5M per the SEC financials is small in absolute terms. The rating does not constitute personalized advice; it summarizes the source-derived evidence.

Per the SEC financials, revenue declined from $46.9M in FY 2024 to $38.7M in FY 2025, while reported net income of $24.6M in FY 2025 sits well above operating income of $4.1M, a gap the source data does not explain. The reported net margin of 63.5% in the market data is consistent with that unusual divergence and warrants verification. ROIC is 16.2% per the market data. The Altman Z-Score of 2.5 and Piotroski F-Score of 6 of 9, per the Roarable RQD rating, together point to a moderate balance sheet, and Debt/Equity is 0.5; the debt figure itself is N/A in the filings.

Per the recent news data, four items are tagged to IDXG, all with a YELLOW light and MARKET WIRE impact label. The most substantive item is a headline reporting pricing for a 3.1M share offering at $6-$7 amid Nasdaq listing plans, which signals dilution and capital-raising activity. The remaining three items are calendar and chart pages with generic summaries and no company-specific detail. The market data shows a single-session change of 15.56%. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

• What is the composition of the reported $24.6M FY 2025 net income relative to $4.1M operating income, and is it recurring?
• What are the size, price, and use of proceeds of the announced 3.1M share offering, and what is its dilution impact?
• What is the total debt balance, since the debt figure is N/A in the filings despite a reported Debt/Equity of 0.5?
• What are the company's products, customers, and revenue drivers behind the decline from $46.9M to $38.7M in revenue?
• Why are the trailing and forward EPS and P/E unavailable, and what is the share count?